This symposium will provide participants with an overview of frailty as an important concept in pharmacoepidemiology. We will present aspects pertaining to measuring frailty as a clinically relevant outcome, as well as an important confounder, or effect modifier. We will address challenges of measuring frailty from secondary data sources (i.e., claims data) in studies evaluating medication use, safety and effectiveness in vulnerable populations.
The main objectives of the symposium are: (1) to provide an overview on the concept of frailty and its measurement as applied in pharmacoepidemiologic studies, (2) to discuss the challenges related to defining, identifying, and measuring frailty from different data sources in vulnerable populations, and (3) to discuss future directions in addressing existing methodological challenges in incorporating measures of frailty in pharmacoepidemiologic studies. This symposium will provide useful insights to researchers involved in or seeking additional expertise in conducting pharmacoepidemiologic studies in vulnerable populations. Participants will have the opportunity to engage in discussions with the speakers and other attendees.
Topics and Speakers: (1) 5 W’s of Frailty: who, what, when, where and why - Todd Manini, Associate Professor, Institute on Aging, Department of Aging and Geriatric Research, University of Florida;
(2) You may know frailty when you see it, but how do you measure it? Daniela Moga, Associate Professor, Department of Pharmacy Practice and Science, University of Kentucky;
(3) How to Incorporate Frailty in Pharmacoepidemiology, in Just 5 Applications Andrew Zullo, Assistant Professor of Health Services, Policy and Practice, Assistant Professor of Epidemiology, Brown University;
(4) Current Methodological Challenges and Future Directions for Frailty Measurement in Pharmacoepidemiology Jennifer Lund, Associate Professor, Department of Epidemiology, University of North Carolina at Chapel Hill.
The session will be moderated by Dae Kim, Associate Professor, Department of Medicine/Division of Pharmacoepidemiology & Pharmacoeconomics, Brigham and Women’s Hospital and Harvard Medical School, and Scott Martin Vouri, Clinical Assistant Professor, Department of Pharmaceutical Outcomes & Policy, UF College of Pharmacy.